VIENNA, NEUSS, Germany and NEW YORK, April 28 /PRNewswire/ -- Sanochemia Diagnostics International, an associated company of Sanochemia Pharmazeutika AG, Vienna, has secured distribution rights of AmniSure(TM) for Germany, Austria, Switzerland and UK. This PROM rapid test (PROM= premature rupture of fetal membranes) is used for pregnant women presenting for assessment of membranes rupture. It is manufactured by N-Dia Inc, New York.
AmniSure(TM) is a point-of-care-test (POCT) which detects premature ruptures of the amniotic membrane. This indication is one of the most frequent reasons for premature birth and besides other complications during pregnancy counts responsible for an increased mortality risk for mother and baby. This clinical condition may be in question in up to 35% of all pregnancies. Therefore the exact and premature proof of a membrane rupture helps to reduce in this case complications during pregnancy. AmniSure(TM) has been approved by the FDA as the only PROM test worldwide to depict such clinical conditions.
With AmniSure(TM) Sanochemia Diagnostics takes another important step to consolidate its franchise in the in-vitro diagnostic markets of "Women' s health". It has been launched in Germany and will be launched in Austria, Switzerland and the UK shortly. "Due to our strong presence on important European markets, we hope to take a significant share of the market soon. That means a great progress in our strategic goals", said Dr. Bruno Rosen, Managing Director of Sanochemia Diagnostics Deutschland GmbH.
"N-Dia is committed to the field of diagnostics of pregnancy complications. We are happy to develop core European markets with Sanochemia Diagnostics", says Dr. Michael Friedman, CEO of N-Dia, Inc.
Sanochemia Pharmazeutika AG is an Austrian research-based pharmaceutical corporation specialised in the research and development of therapeutics for the indication of the central nervous system. In addition to the development and production of synthetic agents the company dedicates to the sale of contrast media and diagnostics via the associated company Sanochemia Diagnostics International, based in Neuss near Dusseldorf, Germany.
N-Dia, Inc. is based in New York, USA. The compay's main focus is on developing and marketing products for rapid diagnostics. Most of N-Dia's products utilize monoclonal antibodies to detect proteins associated with particular diseases. The company has developed a platform technology that minimizes false positive and false negative results in diagnostic testing and markets its products through a worldwide network of distributors.
SANOCHEMIA Pharmazeutika AG